Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trial

PURPOSE: Interferon is approved for adjuvant treatment of patients with stage IIb/III melanoma. The toxicity and uncertainty regarding survival benefits of interferon have qualified its acceptance, despite significant durable relapse prevention in a fraction of patients. Predictive biomarkers that w...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Gogas, Helen, Dafni, Urania, Koon, Henry, Spyropoulou-Vlachou, Maria, Metaxas, Yannis, Buchbinder, Elizabeth, Pectasides, Eirini, Tsoutsos, Dimosthenis, Polyzos, Aristidis, Stratigos, Alexandros, Markopoulos, Christos, Panagiotou, Petros, Fountzilas, George, Castana, Ourania, Skarlos, Pantelis, Atkins, Michael B, Kirkwood, John M
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2010
Teme:
Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC2988721/
https://ncbi.nlm.nih.gov/pubmed/21044351
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1479-5876-8-108
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki